A DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF ARIPIPRAZOLE IN CHILDREN AND ADOLES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 0135 这项研究针对患有抽动症(TD)的儿童和青少年及其相关的共病精神障碍的治疗提出了重要的公共卫生和生活质量问题。到目前为止，唯一正式批准的治疗TD的药物是氟哌啶醇和吡莫齐特，这两种典型的抗精神病药物已知具有显著的不良副作用，如迟发性运动障碍、体重增加和认知迟钝(Green，2001)。此外，有关TD并存精神障碍的治疗数据也很少。因此，需要更有效和更可耐受的治疗方法。 有一些初步证据表明，低到中等剂量的阿立哌唑可以减少患有品行障碍的青少年的攻击性，并且耐受性良好(Findling等人，2003年)。阿立哌唑具有独特的作用机制，其特点是对多巴胺和5-羟色胺系统产生部分激动剂-拮抗剂作用。因此，阿立哌唑改善青少年TD患者的爆发性发作和抽动是有理论依据的。联合调查人员在一系列病例中获得的初步数据表明，阿立哌唑是一种有效的治疗抽动和抽动障碍年轻人爆发性发作的药物，耐受性相当好。这项提案将解决这一潜在的令人兴奋的治疗方法，以治疗患有TD和爆炸性发作的青少年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 0135 This study addresses important public health and quality of life concerns regarding the treatment of children and adolescents with Tourette's Disorder (TD) and the associated comorbid psychiatric disorders. To date, the only formally approved treatments for TD are haloperidol and pimozide, typical neuroleptic agents known to have significant and unwanted side effects such as tardive dyskinesia, weight gain and cognitive blunting (Green, 2001). In addition, there is little data on the treatment of comorbid psychiatric disorders in TD. Thus, more efficacious and tolerable treatments are needed. There is some preliminary evidence that aripiprazole can reduce aggression in youth with conduct disorder in low-moderate doses, and was well tolerated (Findling et al., 2003). Aripiprazole has a unique mechanism of action, characterized by partial agonist-antagonist effects on the dopamine and serotonin systems. Therefore, there is a theoretical basis to anticipate that aripiprazole will ameliorate both explosive outbursts and tics in youth with TD. Preliminary data obtained in a case series by the co-investigators has suggested that aripiprazole is effective and reasonably well tolerated as a treatment for both tics and explosive outbursts in young individuals with Tourette's Disorder. This proposal will address this potentially exciting treatment for youth with TD and explosive outbursts.